Savant Capital, LLC Akebia Therapeutics, Inc. Transaction History
Savant Capital, LLC
- $17.8 Billion
- Q3 2025
A detailed history of Savant Capital, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Savant Capital, LLC holds 18,967 shares of AKBA stock, worth $32,243. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,967
Previous 18,967
-0.0%
Holding current value
$32,243
Previous $69,000
26.09%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
190Shares Held
121MCall Options Held
267KPut Options Held
280K-
Vanguard Group Inc Valley Forge, PA15.5MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...